Company Profile
Shanghai Henlius Biotech provides the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis.
Its portfolio also includes HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer, HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn's disease, and pediatric Crohn's disease, and HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and recurrent non-small cell lung cancer.
It also develops HANSIZHUANG, a serplulimab injection to treat colorectal cancer, gastric carcinoma, and limited-stage small cell lung cancer. Its portfolio also includes HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration, HLX22 to treat of metastatic gastroesophageal junction cancer and gastric cancer, HLX6018 to treat idiopathic pulmonary fibrosis, HLX22, HLX42, HLX43, and HLX53 to treat solid tumors, HLX11 to treat breast cancer, HLX14 to treat osteoporosis, and HLX15 for multiple myeloma.
The company operates in Mainland China, the Asia Pacific, North and South America, Europe, and Oceania. Founded in 2010, the company is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical Development Co., Ltd.